Melatonin Supplementation in Adult Patients With Atopic Dermatitis: A Randomized Clinical Trial
Journal of Pineal Research · 2026-03 · 78 (2)
DOI: 10.1111/jpi.70130 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Pineal Research, online erschienen am 06.03.2026. Verfasst von Zinat Heidari und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Melatonin, Dermatitis, Atopic, Dietary Supplements. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Research Council of Alborz University of Medical Sciences.
Abstract (Originalsprache)
This study aimed to evaluate the effects of melatonin supplementation on disease severity, sleep quality, and quality of life in adult patients with atopic dermatitis (AD). This study was designed as a randomized, double‐blind, placebo‐controlled clinical trial involving adult patients with mild to moderate AD. Eligible participants were randomly assigned to receive either a 10 mg melatonin tablet or a matching placebo once daily for 4 weeks. The primary outcome was the severity of AD, assessed by SCORAD index at baseline and after 4 weeks of supplementation. Secondary outcomes included the intensity of pain (NPRS), pruritus severity (Pruritus‐NRS), sleep quality (ADSS), and quality of life (DLQI). Eighty patients completed the study. The mean age (Standard deviation) of the patients was 33.26 (12.57) years, and 32 patients (40%) were male. The SCORAD, Pruritus‐NRS, 12‐PSS, ADSS, and DLQI indices improved significantly ( p ‐values of < 0.001, 0.006, 0.011, < 0.05, and 0.003, respectively) after 4 weeks of supplementation. However, melatonin supplementation did not improve the NPRS ( p ‐value: 0.063). No patient reported an adverse effect throughout the study. Melatonin supplementation in adult patients with mild to moderate AD effectively improved disease severity, sleep quality, and quality of life, without any reported adverse effects. However, due to limitations of our study, further research is required to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Clinical Pharmacy, School of Pharmacy, Alborz University of Medical Sciences, Karaj, Iran.
- Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Dermatology, Alborz University of Medical Sciences, Karaj, Iran.
- Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
- Department of Pharmaceutics, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
ORCID-Profile: Zinat Heidari
Förderung
- Research Council of Alborz University of Medical Sciences
Zitieren
APA
Heidari, Z., Gharibi, G., Alaeen, H., Ghadrdan, E., Shahrestanaki, E., Sadeghi-Ghadi, Z., Sahebkar, A., & Daei, M. (2026). Melatonin Supplementation in Adult Patients With Atopic Dermatitis: A Randomized Clinical Trial. Journal of Pineal Research, 78(2). https://doi.org/10.1111/jpi.70130
Vancouver
Heidari Z, Gharibi G, Alaeen H, Ghadrdan E, Shahrestanaki E, Sadeghi-Ghadi Z, et al. Melatonin Supplementation in Adult Patients With Atopic Dermatitis: A Randomized Clinical Trial. Journal of Pineal Research. 2026;78(2). doi:10.1111/jpi.70130
BibTeX
@article{Heidari2026,
author = {Heidari, Zinat and Gharibi, Ghazal and Alaeen, Hoorieh and Ghadrdan, Elliyeh and Shahrestanaki, Ehsan and Sadeghi-Ghadi, Zeynab and Sahebkar, Amirhossein and Daei, Maryam},
title = {Melatonin Supplementation in Adult Patients With Atopic Dermatitis: A Randomized Clinical Trial},
journal = {Journal of Pineal Research},
year = {2026},
volume = {78},
number = {2},
doi = {10.1111/jpi.70130}
}
EUVIMED